Research Focus
Addiction is a complex disease resulting from the interaction of genetic predisposition and environmental factors. In particular, genetic polymorphisms that regulate neurotransmitter systems such as dopamine, serotonin and GABA play a critical role in predisposition to addiction. For example, variations in DRD2 and COMT genes are associated with differences in reward mechanisms. Furthermore, the CYP450 enzyme family, which is involved in the metabolism of drugs used in addiction treatment (e.g. methadone, naltrexone), is at the center of pharmacogenetic studies.
The Addiction Working Group, which operates within the Center for Personalized Treatment (KİMER), continues its work with an innovative vision aiming to analyze the genetic and pharmacogenetic basis of addiction. This group focuses on the following goals with the aim of developing individualized treatment strategies:
Goals of the Working Group:
- Pharmacogenetic Perspective: To examine the role of genetic factors in the metabolism of drugs used in addiction treatment
- Genetic Predisposition: Building models that can predict risk by identifying genetic variations that pose a risk for addiction.
- Clinical Applications: Developing genetic-based personalized treatment panels that can be used in the treatment of addiction and risk assessment tools for addiction prevention.
These focus areas have the potential for individualized treatment of addiction at both the scientific and clinical level. By integrating genetic data into clinical practice, the working group aims to develop strategies that optimize each individual's response to treatment.